Through collaborations between biopharma and diagnostic developers the field of oncology is advancing to ensure highly-personalized therapies and diagnostics are a part of the next gold standard of care. While the utility of monitoring molecular residual disease (MRD) has been explored in several indications, monitoring disease recurrence of low tumor mutational burden (TMB) cancers remains a challenge. In these cases, an ultra-sensitive, tumor-informed ctDNA-based MRD detection platform is needed.

In this webinar, you’ll learn about a case study pursued in collaboration with Geneos Therapeutics and Personalis to utilize a tumor-informed ctDNA assay to retrospectively analyze clinical response to a class of personalized immunotherapies developed against tumor-specific neoantigens in advanced hepatocellular cancer (HCC) patients. The results indicated changes in ctDNA levels relative to baseline following treatment were detected prior to confirmation of clinical response by RECIST 1.1 and correlated well with disease status.

About Personalis:
Personalis is transforming the active management of cancer through more personalized testing. 

About Geneos Therapeutics:
Geneos Therapeutics a clinical stage biotherapeutic company, believes that personalized therapies will serve an important role in new treatment paradigms for cancer.